Please use this identifier to cite or link to this item:
Title: Antibodies in oncology.
Austin Authors: Pillay, Vinochani;Gan, Hui K ;Scott, Andrew M 
Affiliation: Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia
Issue Date: 5-Apr-2011
Publication information: New Biotechnology 2011; 28(5): 518-29
Abstract: Monoclonal antibodies (mAbs) have become one of the largest classes of new therapeutic agents approved for use in oncology, and have revolutionised the treatment of many human malignancies. Clinically useful mAbs can function through several different mechanisms, including inhibition of tumour-related signalling, induction of apoptosis, inhibition of angiogenesis, enhancing host immune response against cancer and targeted delivery of payloads (such as toxins, cytotoxic agents or radioisotopes) to the tumour site. The increasing knowledge of key molecules and cellular pathways involved in tumour induction and progression has led to a rise in the proportion of therapeutic mAbs entering clinical trials. These mAbs consist of various conventional or recombinant, murine, humanised, chimeric or fully human and fusion constructs. In this review, we provide an overview of mAbs approved for use in clinical oncology and those currently in clinical development. We also discuss the mechanisms of action of anti-cancer mAbs, as well as the antigen targets recognised by these antibodies.
Gov't Doc #: 21473941
DOI: 10.1016/j.nbt.2011.03.021
Journal: New biotechnology
Type: Journal Article
Subjects: Animals
Antibodies, Monoclonal.immunology.therapeutic use
Antibodies, Neoplasm.immunology
Antigens, Neoplasm.immunology
Antineoplastic Agents.immunology.therapeutic use
Immunologic Techniques
Neoplasms.drug therapy.immunology
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.